ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives MHLW’s Approval to Treat HIV 1 Infection

 ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives MHLW’s Approval to Treat HIV 1 Infection

ViiV Healthcare’s Dovato (dolutegravir/lamivudine) Receives MHLW’s Approval to Treat HIV 1 Infection

Shots:

  • The approval is based on GEMINI 1 & 2 studies assessing dual drug regimen (dolutegravir 50 mg/lamivudine 300 mg) vs dolutegravir + two NRTIs [tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)] in 1400 patients with HIV-1 infection aged> 12yrs. weighing at least 40kg
  •  The GEMINI 1 & 2 study results demonstrated non-inferior efficacy based on plasma HIV-1 RNA <50copies/ml @48wks., safety is consistent with product labeling  
  • Dovato (qd) is a single-pill, 2-drug regimen to treat naïve HIV infection, combining an integrase inhibitor (INI) with the nucleoside reverse transcriptase inhibitor (NRTI) and is an authorized therapy in the EU for HIV-1 infection

Click here ­to­ read full press release/ article | Ref: GSK | Image: ViiV Healthcare

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post